Roche Agreement

Sigma-Aldrich and Roche are currently working to ensure that processes are in place so that customers experience an uninterrupted transition during ordering, service or delivery. After conversion, a link to the Sigma Aldrich page will be displayed on the product pages on In order to support quality and sustainability of field storage programs, Roche and Sigma-Aldrich have jointly decided to switch to Sigma Aldrich solutions for biochemical reagents currently available in De Roche Prime Supply (RPS) manual and automated programs. For more information, click here. As part of the agreement, Roche will work with the Ministry of Health to carry out various activities, such as. B: disease awareness programmes, screening to promote early detection, establishment of two centres of excellence, improvement of diagnostic facilities in treatment centres, training of specialists, creation of a national cancer registry to better understand the burden of diseases and work towards setting national treatment targets. Efforts are also being made to improve access to breast cancer treatment under the national health insurance scheme. At Roche, we are driven by our deep commitment to providing our customers with the best products and services. We would like to inform you of an important change in how to access our reagent-based biochemicals, which include kits and enzymes for cell analysis, proteomics and conventional PCR applications. Roche has signed a global distribution agreement with Sigma-Aldrich that allows you, the customer, to benefit from their strong e-commerce and logistics skills. While Roche remains the legal manufacturer of these products, they are available from July 1 exclusively through Sigma-Aldrich`s distribution channels.

You will find more information in the press release or in the FAQ documents Below you will find an interactive list of the products contained in this agreement and which are now available exclusively through Sigma-Aldrich. You will find all relevant legal exclusions by clicking on the “Show Disclaimer” button to the right of the product name. Note: Links to product numbers guide you outside of Roche to the website of our exclusive global business partner. The powerful combination of high-quality rock products and Sigma Aldrich service excellence creates a strong promise of value for these products in life-science research. As part of the agreement, Sigma-Aldrich will use its sales, marketing and e-commerce expertise and leverage the strength of its relationships with the scientific community to showcase and distribute Proteomics, cell analysis and Roche`s classic PCR reagents and kits. In this collaboration, Lead Pharma and Roche will work together in research activities, up to the selection of a preclinical candidate, after which Roche will be responsible for global development and commercialization. In accordance with the terms of the agreement, Lead Pharma receives a deposit of €10 million. it is entitled to research funding and preclinical payments.

The total amount of potential payments, including research, development, regulation and distribution, can amount to €260 million, plus royalties on global sales. “Through our pioneering work in RNA biology, we have set up a platform for the development and adaptation of active substance research tools that allow us to predict and validate the structure of RNA targets, locate drug pockets, identify drug-like outcomes, and implement medical chemistry programs to detect a new class of anti-RNA drugs for Power, selectivity and safety are optimized…

Most Popular

Get the fresh basketball buzz of your favorite teams and players.

Copyright © 2018 var sc_project=2306163; var sc_invisible=1; var sc_security="476c3dd1";

Analytics Made Easy - StatCounter

To Top